News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,075 Results
Type
Article (14464)
Company Profile (101)
Press Release (263509)
Multimedia
Podcasts (71)
Webinars (14)
Section
Business (88383)
Career Advice (468)
Deals (15442)
Drug Delivery (82)
Drug Development (36777)
Employer Resources (50)
FDA (6413)
Job Trends (6248)
News (150914)
Policy (14139)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (451)
Accelerated approval (25)
ADA (10)
Adcomms (9)
Allergies (98)
Alliances (23324)
ALS (72)
Alzheimer's disease (523)
Antibody-drug conjugate (ADC) (162)
Approvals (6719)
Artificial intelligence (273)
ASCO (113)
Autoimmune disease (78)
Automation (21)
Bankruptcy (151)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (152)
Biotechnology (39)
Bladder cancer (51)
Brain cancer (40)
Breast cancer (210)
Cancer (1728)
Cardiovascular disease (201)
Career advice (422)
Career pathing (14)
CAR-T (66)
CDC (7)
Cell therapy (199)
Cervical cancer (20)
Clinical research (32596)
Collaboration (948)
Commercialization (1)
Company closure (1)
Compensation (398)
Complete response letters (46)
COVID-19 (786)
CRISPR (54)
C-suite (641)
Cystic fibrosis (62)
Data (2540)
Decentralized trials (1)
Denatured (19)
Depression (59)
Dermatology (15)
Diabetes (167)
Diagnostics (1455)
Digital health (16)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (163)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (99)
Earnings (34225)
Editorial (24)
Employer branding (4)
Employer resources (46)
Events (39924)
Executive appointments (612)
FDA (7811)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (549)
Gene editing (86)
Generative AI (27)
Gene therapy (202)
GLP-1 (491)
Government (1430)
Grass and pollen (4)
Guidances (173)
Healthcare (3639)
Hematology (66)
HIV (17)
Huntington's disease (12)
IgA nephropathy (52)
Immunology and inflammation (84)
Immuno-oncology (30)
Indications (96)
Infectious disease (885)
Inflammatory bowel disease (86)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (138)
Interviews (60)
IPO (5929)
IRA (33)
Job creations (2061)
Job search strategy (375)
JPM (29)
Kidney cancer (12)
Labor market (36)
Layoffs (210)
Leadership (10)
Legal (3450)
Liver cancer (26)
Longevity (10)
Lung cancer (236)
Lymphoma (159)
Machine learning (15)
Management (17)
Manufacturing (562)
Marketing (1)
MASH (91)
Medical affairs (1)
Medical device (1313)
Medtech (1328)
Mergers & acquisitions (10038)
Metabolic disorders (568)
mRNA (63)
Multiple sclerosis (59)
NASH (15)
Neurodegenerative disease (109)
Neuropsychiatric disorders (48)
Neuroscience (1057)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (608)
Now hiring (24)
Obesity (291)
Opinion (151)
Ovarian cancer (65)
Pain (136)
Pancreatic cancer (71)
Parkinson's disease (110)
Partnered (12)
Patents (279)
Patient recruitment (173)
Peanut (15)
People (30237)
Pharmaceutical (60)
Pharmacy benefit managers (19)
Phase 1 (8444)
Phase 2 (13773)
Phase 3 (12434)
Pipeline (3485)
Policy (148)
Postmarket research (1403)
Preclinical (3409)
Press Release (25)
Prostate cancer (114)
Psychedelics (22)
Radiopharmaceuticals (159)
Rare diseases (471)
Real estate (2668)
Recruiting (19)
Regulatory (11396)
Reports (16)
Research institute (581)
Resumes & cover letters (56)
Rett syndrome (11)
RNA editing (9)
RSV (25)
Schizophrenia (87)
Series A (113)
Series B (64)
Service/supplier (2)
Sickle cell disease (55)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1652)
State (2)
Stomach cancer (6)
Supply chain (64)
Tariffs (71)
The Weekly (50)
Vaccines (273)
Venture capital (40)
Weight loss (172)
Women's health (49)
Worklife (4)
Date
Today (33)
Last 7 days (180)
Last 30 days (894)
Last 365 days (10358)
2026 (5213)
2025 (10707)
2024 (12495)
2023 (14247)
2022 (19558)
2021 (20072)
2020 (19043)
2019 (14885)
2018 (11713)
2017 (13887)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10892)
Location
Africa (323)
Alabama (20)
Alaska (1)
Arizona (88)
Arkansas (4)
Asia (21256)
Australia (2740)
California (3929)
Canada (1789)
China (743)
Colorado (175)
Connecticut (155)
Delaware (168)
Europe (41668)
Florida (749)
Georgia (76)
Hawaii (1)
Idaho (11)
Illinois (459)
India (66)
Indiana (306)
Iowa (2)
Japan (352)
Kansas (84)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (501)
Massachusetts (3179)
Michigan (55)
Minnesota (205)
Mississippi (1)
Missouri (38)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1750)
New Mexico (7)
New York (1129)
North Carolina (740)
North Dakota (2)
Northern California (1857)
Ohio (94)
Oklahoma (5)
Oregon (18)
Pennsylvania (854)
Puerto Rico (18)
Rhode Island (18)
South America (508)
South Carolina (11)
Southern California (1729)
Tennessee (66)
Texas (560)
United States (15600)
Utah (66)
Vermont (1)
Virginia (209)
Washington D.C. (42)
Washington State (288)
West Virginia (1)
Wisconsin (50)
Wyoming (1)
278,075 Results for "syros pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC.
November 13, 2024
·
2 min read
·
Tristan Manalac
Genetown
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024
Syros Pharmaceuticals announced the grant of a restricted stock unit award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros.
April 2, 2024
·
1 min read
Genetown
Syros to Participate in Upcoming May 2024 Investor Conferences
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced that company management will participate in a fireside chat at two upcoming investor conferences.
May 7, 2024
·
1 min read
Press Releases
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
April 15, 2025
·
1 min read
Business
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
9 min read
Business
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Syros Pharmaceuticals announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
May 7, 2024
·
1 min read
Genetown
Syros to Participate in Upcoming Investor Conferences - November 21, 2023
Syros Pharmaceuticals today announced that company management will participate in a fireside chat at two upcoming investor conferences.
November 21, 2023
·
1 min read
Genetown
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Syros Pharmaceuticals today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference.
February 27, 2024
·
1 min read
Genetown
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
January 8, 2024
·
7 min read
Business
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
November 14, 2023
·
9 min read
1 of 27,808
Next
